Please login to the form below

Not currently logged in
Email:
Password:

Tanzeum

This page shows the latest Tanzeum news and features for those working in and with pharma, biotech and healthcare.

Sanofi's lixisenatide is back under FDA review

Sanofi's lixisenatide is back under FDA review

Meanwhile, new GLP-1 agonists that require dosing just once a week - including Eli Lilly's Trulicity (dulaglutide), GlaxoSmithKline's Tanzeum (albiglutide) AstraZeneca's Bydureon (exenatide) and Novo Nordisk's semaglutide -

Latest news

  • Type 2 diabetes market set to hit $39bn by 2021 Type 2 diabetes market set to hit $39bn by 2021

    Notable examples include two recently approved once-weekly GLP-1 receptor agonists, Tanzeum and Trulicity, and an orally administered GLP-1 receptor agonist, OG-217SC, which is in phase II development,

  • Novo Nordisk's oral GLP-1 analogue looks set for phase III Novo Nordisk's oral GLP-1 analogue looks set for phase III

    If the injectable version is approved it will have to compete with a number of similar products on the market - notably AstraZeneca's Bydureon (exenatide), GlaxoSmithKline's Tanzeum/Eperzan (albiglutide) and

  • Novo Nordisk's Xultophy debuts in Switzerland Novo Nordisk's Xultophy debuts in Switzerland

    s Tanzeum (albiglutide), AstraZeneca's Bydureon (exenatide) and Eli Lilly's recently-launched Trulicity (dulaglutide) offering once-weekly rather than once-daily injections.

  • Lilly launches GLP-1 agonist Trulicity in US Lilly launches GLP-1 agonist Trulicity in US

    Lilly launches GLP-1 agonist Trulicity in US. Once-weekly treatment will challenge GSK's Tanzeum, AZ's Bydureon and Novo's Victoza in diabetes. ... Lilly has launched Trulicity in the same price region as Victoza but above Tanzeum, which GSK is selling

  • FDA approves Lilly’s GLP-1 diabetes drug Trulicity FDA approves Lilly’s GLP-1 diabetes drug Trulicity

    FDA approves Lilly’ s GLP-1 diabetes drug Trulicity. The once-weekly treatment is set to compete with Bydureon, Tanzeum and Victoza. ... Competition is heating up, however, and GlaxoSmithKline has won approval for once-weekly albiglutide in the US

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics